glp 1 drugs thyroid cancer GLP-1 agonist like Ozempic do not increase risk glp-1 drugs and thyroid cancer

MapambaDSabiILalashowiJSauliEBuzaJOlomiWet al

Second, as CG-rich genes are preferentially regulated at the transcriptional elongation stage, this might give them a selective advantage of becoming rapidly upregulated on appropriate stimuli (Hargreaves et al., 2009

Zhu YX, Kortuem KM, Stewart AK

Improved insulin signaling helps the body process glucose more efficiently, reducing the tendency to store excess energy as fat

We examine the history of attempts to develop oral GLP-1 therapies, the structural biology of non-peptide GLP-1 receptor activation, the pharmacokinetic advantages of orforglipron's small-molecule architecture, the complete Phase 2 and Phase 3 clinical dataset, comparisons with both oral and injectable GLP-1 agonists, the manufacturing and cost implications of small-molecule production, the safety profile across all completed trials, and the regulatory pathway and timeline for approval